JP2009511468A - 抗肥満組成物 - Google Patents
抗肥満組成物 Download PDFInfo
- Publication number
- JP2009511468A JP2009511468A JP2008534469A JP2008534469A JP2009511468A JP 2009511468 A JP2009511468 A JP 2009511468A JP 2008534469 A JP2008534469 A JP 2008534469A JP 2008534469 A JP2008534469 A JP 2008534469A JP 2009511468 A JP2009511468 A JP 2009511468A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- composition
- weight
- obesity
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 183
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 65
- 239000000284 extract Substances 0.000 claims abstract description 173
- 240000006891 Artemisia vulgaris Species 0.000 claims abstract description 46
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 45
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 42
- 239000004480 active ingredient Substances 0.000 claims abstract description 34
- 208000008589 Obesity Diseases 0.000 claims abstract description 30
- 235000020824 obesity Nutrition 0.000 claims abstract description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 241000723353 Chrysanthemum Species 0.000 claims abstract 19
- 244000062730 Melissa officinalis Species 0.000 claims description 82
- 239000000843 powder Substances 0.000 claims description 23
- 241000196324 Embryophyta Species 0.000 claims description 15
- 244000269722 Thea sinensis Species 0.000 claims description 15
- 239000000835 fiber Substances 0.000 claims description 15
- 235000009569 green tea Nutrition 0.000 claims description 14
- 229940094952 green tea extract Drugs 0.000 claims description 13
- 235000020688 green tea extract Nutrition 0.000 claims description 13
- 235000020710 ginseng extract Nutrition 0.000 claims description 12
- 235000015701 Artemisia arbuscula Nutrition 0.000 claims description 10
- 235000002657 Artemisia tridentata Nutrition 0.000 claims description 10
- 244000000626 Daucus carota Species 0.000 claims description 8
- 235000002767 Daucus carota Nutrition 0.000 claims description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 8
- 235000008434 ginseng Nutrition 0.000 claims description 8
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 6
- 229940025902 konjac mannan Drugs 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims description 4
- 244000215068 Acacia senegal Species 0.000 claims description 4
- 229920000189 Arabinogalactan Polymers 0.000 claims description 4
- 239000001904 Arabinogalactan Substances 0.000 claims description 4
- 229920002907 Guar gum Polymers 0.000 claims description 4
- 229920000084 Gum arabic Polymers 0.000 claims description 4
- 229920002488 Hemicellulose Polymers 0.000 claims description 4
- 229920001202 Inulin Polymers 0.000 claims description 4
- 244000134552 Plantago ovata Species 0.000 claims description 4
- 235000003421 Plantago ovata Nutrition 0.000 claims description 4
- 239000009223 Psyllium Substances 0.000 claims description 4
- 239000000205 acacia gum Substances 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 239000000783 alginic acid Substances 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 229960001126 alginic acid Drugs 0.000 claims description 4
- 150000004781 alginic acids Chemical class 0.000 claims description 4
- 235000019312 arabinogalactan Nutrition 0.000 claims description 4
- 239000000665 guar gum Substances 0.000 claims description 4
- 235000010417 guar gum Nutrition 0.000 claims description 4
- 229960002154 guar gum Drugs 0.000 claims description 4
- 239000010903 husk Substances 0.000 claims description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 4
- 229940029339 inulin Drugs 0.000 claims description 4
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims description 4
- 229920005610 lignin Polymers 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 229940070687 psyllium Drugs 0.000 claims description 4
- 229920001100 Polydextrose Polymers 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 239000001259 polydextrose Substances 0.000 claims description 3
- 235000013856 polydextrose Nutrition 0.000 claims description 3
- 229940035035 polydextrose Drugs 0.000 claims description 3
- 241000208340 Araliaceae Species 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 44
- 210000004369 blood Anatomy 0.000 abstract description 26
- 239000008280 blood Substances 0.000 abstract description 26
- 230000037396 body weight Effects 0.000 abstract description 25
- 210000000577 adipose tissue Anatomy 0.000 abstract description 24
- 235000012000 cholesterol Nutrition 0.000 abstract description 13
- 239000008103 glucose Substances 0.000 abstract description 12
- 210000002149 gonad Anatomy 0.000 abstract description 11
- 238000013116 obese mouse model Methods 0.000 abstract description 11
- 210000001789 adipocyte Anatomy 0.000 abstract description 9
- 230000001965 increasing effect Effects 0.000 abstract description 9
- 150000002632 lipids Chemical class 0.000 abstract description 9
- 210000004185 liver Anatomy 0.000 abstract description 9
- 230000007423 decrease Effects 0.000 abstract description 8
- 210000001596 intra-abdominal fat Anatomy 0.000 abstract description 8
- 238000013224 high-fat diet-induced obese mouse Methods 0.000 abstract description 7
- 210000003205 muscle Anatomy 0.000 abstract description 7
- 210000003934 vacuole Anatomy 0.000 abstract description 6
- 238000008214 LDL Cholesterol Methods 0.000 abstract description 5
- 101710095342 Apolipoprotein B Proteins 0.000 abstract description 4
- 102100040202 Apolipoprotein B-100 Human genes 0.000 abstract description 4
- 230000006372 lipid accumulation Effects 0.000 abstract description 4
- 230000001629 suppression Effects 0.000 abstract description 3
- 230000004580 weight loss Effects 0.000 abstract description 3
- 206010020880 Hypertrophy Diseases 0.000 abstract description 2
- 210000000579 abdominal fat Anatomy 0.000 abstract description 2
- 231100000272 reduced body weight Toxicity 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 34
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 22
- 238000011282 treatment Methods 0.000 description 16
- 210000004003 subcutaneous fat Anatomy 0.000 description 14
- 238000009472 formulation Methods 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 239000002775 capsule Substances 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000004584 weight gain Effects 0.000 description 8
- 235000019786 weight gain Nutrition 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 240000000249 Morus alba Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- -1 antibacterials Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 6
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 6
- 229940030961 sorghum extract Drugs 0.000 description 6
- 238000002591 computed tomography Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 235000014679 Morus rubra var. rubra Nutrition 0.000 description 4
- 235000014677 Morus rubra var. tomentosa Nutrition 0.000 description 4
- 206010033307 Overweight Diseases 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 229960004425 sibutramine Drugs 0.000 description 4
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 240000005250 Chrysanthemum indicum Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 235000010654 Melissa officinalis Nutrition 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000007963 capsule composition Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000005265 energy consumption Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 210000001624 hip Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229960001243 orlistat Drugs 0.000 description 3
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 3
- 239000012285 osmium tetroxide Substances 0.000 description 3
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229960003562 phentermine Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 229940002552 xenical Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 235000003826 Artemisia Nutrition 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 235000009052 artemisia Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- RAZOKRUZEQERLH-UHFFFAOYSA-N capillin Chemical compound CC#CC#CC(=O)C1=CC=CC=C1 RAZOKRUZEQERLH-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 2
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QKPLRMLTKYXDST-NSEZLWDYSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;hydrochloride Chemical compound Cl.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O QKPLRMLTKYXDST-NSEZLWDYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 102100022451 Actin-related protein T1 Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010029777 actin interacting protein 1 Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- GHNBEBDYYSVNEK-UHFFFAOYSA-N capillon Natural products CC=CC=CC(=O)C1=CC=CC=C1 GHNBEBDYYSVNEK-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229940045623 meridia Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical class OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
さらに、本発明は、活性成分としてメリッサ抽出物とヨモギ抽出物とキク抽出物とを含む抗肥満組成物、メリッサ抽出物とヨモギ抽出物とキク抽出物との混合物の使用法、及び前記組成物を用いる肥満抑制方法を提供する。
本組成物が遺伝性肥満マウス又は高脂肪食誘導肥満マウスに投与されると、本組成物は体重、体脂肪及び生殖腺脂肪を減少し、血中コレステロール値及び肥満関連血糖値を低下する。
また、本組成物は脂肪細胞の肥大化と、脂質液胞のサイズ及び数を減少することによって肝臓における脂質蓄積と、を阻害する。 さらに、ヒト臨床試験では、本組成物により、体重、PIBW、体脂肪、特に内臓脂肪、アポリポタンパク質B濃度、全コレステロール/HDLコレステロールの比率及びLDLコレステロール/HDLコレステロールの比率が有意に減少され、アテローム指数が改善され、筋肉質量が増大されることが明らかになる。
かくして、本組成物は抗肥満組成物として、体重の減少及び腹部脂肪、特に内臓脂肪の抑制に有用に適用することができる。
【選択図】図1
Description
現在、20歳以上の成人の65%と30%がそれぞれ過体重と肥満(症)であると判定されている。
開発途上諸国においてさえも、経済的に発展した地域の肥満比率は先進国の比率と比べて低くない。現在、米国及び日本における肥満人口は最大およそ3億人に上っている。毎年、肥満(症)による死者は30万人を超え、肥満(症)に関連する費用は合計でおよそ100億ドルに達している。
オーリスタット(ブランド名:ゼニカル)、フェンテルミン(ブランド名: ファースティン、ザントレックスなど)、及びシブトラミン(ブランド名: リダクティル、メリディアなど)。
かくして、本発明は、抗肥満組成物を製造するためのメリッサ抽出物の新規使用法、抗肥満組成物を製造するためのメリッサ抽出物とキク抽出物との混合物の新規使用法、及び抗肥満組成物を製造するためのメリッサ抽出物とヨモギ抽出物とキク抽出物との混合物の新規使用法を提供するものである。
これらの使用法における抗肥満用組成物の説明は上記と同一である。
本発明がそれに限定されるものではなく、さまざまに例示かつ実践され得ることを明瞭に理解されたい。 次に挙げる実施例により本発明の開示が完全に行われること、本発明の範囲を当業者に完全に示すこと、及び本発明が特許請求の範囲によってのみ規定されることは明らかである。
10g
葉 10g
10g
葉 10g
10g
葉 10g
6g
6g
12g
72g
6g
葉 6g
110mg/g)を混合し前記製剤を作製した(「サンプル7」とする)。
6g
葉 6g
葉を混合し前記製剤を作製した(「比較サンプル」とする)。[129] カプセルの構成物は以下のとおりである。
葉 10g
さらに、喫煙者及び酒飲者の比率はそれぞれ20%及び72%であった。
7)。
本組成物は血中コレステロール値及び肥満関連血糖値を低下する。
Claims (33)
- 活性成分としてメリッサ抽出物を含む抗肥満組成物。
- 請求項1の組成物であって、該組成物が該組成物100重量部に対して0.1〜100重量部のメリッサ抽出物を含むことを特徴とする組成物。
- 活性成分としてメリッサ抽出物とキク抽出物とを含む抗肥満組成物。
- 請求項3の組成物であって、該組成物が該組成物100重量部に対して0.1〜99重量部のメリッサ抽出物及び0.1〜99重量部のキク抽出物を含むことを特徴とする組成物。
- 活性成分としてメリッサ抽出物とヨモギ抽出物とキク抽出物とを含む抗肥満組成物。
- 請求項5の組成物であって、該組成物が該組成物100重量部に対して0.1〜99重量部のメリッサ抽出物、0.1〜99重量部のヨモギ抽出物及び0.1〜99重量部のキク抽出物を含むことを特徴とする組成物。
- 請求項5の組成物であって、抗肥満用の該組成物がメリッサ抽出物とイワヨモギ抽出物とキク抽出物とをそれぞれ、1〜3:0.1〜1:1〜3乾燥重量部の比率で含むことを特徴とする組成物。
- 請求項1〜7の任意の1項の組成物であって、該組成物が植物繊維、緑茶又は人参のうちの少なくとも1つをさらに含むことを特徴とする組成物。
- 請求項8の組成物であって、前記植物繊維がサイリウムハスク、セルロース、ヘミセルロース、結晶セルロース、リグニン、ペクチン、アルギン酸、ポリマンヌロン酸、グアーガム、アラビアガム、アラビノガラクタン、コンニャクマンナン、イヌリン、レバン、ポリデキストロース、難消化性のポリデキストロース及び難消化性のマルトデキストリンのうちの少なくとも1つであることを特徴とする組成物。
- 請求項8の組成物であって、緑茶が緑茶粉末、緑茶抽出液又は緑茶抽出液の粉末であることを特徴とする組成物。
- 請求項8の組成物であって、人参が人参粉末、人参抽出液又は人参抽出液の粉末であることを特徴とする組成物。
- 抗肥満組成物を製造するためのメリッサ抽出物の使用法。
- 請求項10の使用法であって、該組成物が該組成物100重量部に対して0.1〜100重量部のメリッサ抽出物を含むことを特徴とする使用法。
- 抗肥満組成物を製造するためのメリッサ抽出物とキク抽出物との混合物の使用法。
- 請求項14の使用法であって、該組成物が該組成物100重量部に対して0.1〜99重量部のメリッサ抽出物及び0.1〜99重量部のキク抽出物を含むことを特徴とする使用法。
- 抗肥満組成物を製造するためのメリッサ抽出物とヨモギ抽出物とキク抽出物との混合物の使用法。
- 請求項16の使用法であって、該組成物が該組成物100重量部に対して0.1〜99重量部のメリッサ抽出物、0.1〜99重量部のヨモギ抽出物及び0.1〜99重量部のキク抽出物を含むことを特徴とする使用法。
- 請求項12の使用法であって、抗肥満用の該組成物がメリッサ抽出物とイワヨモギ抽出物とキク抽出物とをそれぞれ、1〜3:0.1〜1:1〜3乾燥重量部の比率で含むことを特徴とする使用法。
- 請求項12〜18の任意の1項の使用法であって、該組成物が植物繊維、緑茶又は人参のうちの少なくとも1つをさらに含むことを特徴とする使用法。
- 請求項19の使用法であって、前記植物繊維がサイリウムハスク、セルロース、ヘミセルロース、結晶セルロース、リグニン、ペクチン、アルギン酸、ポリマンヌロン酸、グアーガム、アラビアガム、アラビノガラクタン、コンニャクマンナン、イヌリン、レバン、ポリデキストロース及び難消化性のマルトデキストリンのうちの少なくともの1つであることを特徴とする使用法。
- 請求項19の使用法であって、緑茶が緑茶粉末、緑茶抽出液又は緑茶抽出液の粉末であることを特徴とする使用法。
- 請求項19の使用法であって、人参が人参粉末、人参抽出液又は人参抽出液の粉末であることを特徴とする使用法。
- メリッサ抽出物を含む抗肥満組成物の有効量をそれを必要とする被験者に投与することを含む肥満抑制方法。
- 請求項24の方法であって、該組成物が該組成物100重量部に対して0.1〜100重量部のメリッサ抽出物を含むことを特徴とする方法。
- メリッサ抽出物とキク抽出物とを含む抗肥満組成物の有効量を投与することを含む肥満抑制方法。
- 請求項25の方法であって、該組成物が該組成物100重量部に対して0.1〜99重量部のメリッサ抽出物及び0.1〜99重量部のキク抽出物を含むことを特徴とする方法。
- メリッサ抽出物とヨモギ抽出物とキク抽出物とを含む抗肥満組成物の有効量を投与することを含む肥満抑制方法。
- 請求項27の方法であって、該組成物が該組成物100重量部に対して0.1〜99重量部のメリッサ抽出物、0.1〜99重量部のヨモギ抽出物及び0.1〜99重量部のキク抽出物を含むことを特徴とする方法。
- 請求項27の方法であって、抗肥満用組成物がメリッサ抽出物とヨモギ抽出物とキク抽出物とを1〜3:0.1〜1:1〜3乾燥重量部の比率で含むことを特徴とする方法。
- 請求項23〜29の任意の1項の方法であって、該組成物が植物繊維、緑茶又は人参のうちの少なくとも1つをさらに含むことを特徴とする方法。
- 請求項30の方法であって、前記植物繊維がサイリウムハスク、セルロース、ヘミセルロース、結晶セルロース、リグニン、ペクチン、アルギン酸、ポリマンヌロン酸、グアーガム、アラビアガム、アラビノガラクタン、コンニャクマンナン、イヌリン、レバン、ポリデキストロース及び難消化性のマルトデキストリンのうちの少なくともの1つであることを特徴とする方法。
- 請求項30の方法であって、緑茶が緑茶粉末、緑茶抽出液又は緑茶抽出液の粉末であることを特徴とする方法。
- 請求項30の組成物であって、人参が人参粉末、人参抽出液又は人参抽出液の粉末であることを特徴とする方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2005-0093577 | 2005-10-05 | ||
KR1020050093577A KR100645385B1 (ko) | 2005-10-05 | 2005-10-05 | 비만 억제용 조성물 |
PCT/KR2006/004049 WO2007040377A1 (en) | 2005-10-05 | 2006-10-09 | Antiobesity composition |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009511468A true JP2009511468A (ja) | 2009-03-19 |
JP2009511468A5 JP2009511468A5 (ja) | 2012-07-19 |
JP5284097B2 JP5284097B2 (ja) | 2013-09-11 |
Family
ID=37712520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008534469A Active JP5284097B2 (ja) | 2005-10-05 | 2006-10-09 | 抗肥満組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9155773B2 (ja) |
EP (1) | EP1951275B8 (ja) |
JP (1) | JP5284097B2 (ja) |
KR (1) | KR100645385B1 (ja) |
CN (1) | CN101277710B (ja) |
AU (2) | AU2006297973A1 (ja) |
BR (1) | BRPI0617988A2 (ja) |
CA (1) | CA2624929C (ja) |
ES (1) | ES2581336T3 (ja) |
WO (1) | WO2007040377A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008050301A (ja) * | 2006-08-24 | 2008-03-06 | Prima Meat Packers Ltd | 膵リパーゼ阻害剤 |
JP2016189757A (ja) * | 2015-03-31 | 2016-11-10 | 株式会社東洋新薬 | 除脂肪体重の増加剤 |
JP2020164486A (ja) * | 2019-03-29 | 2020-10-08 | 丸善製薬株式会社 | 抗老化剤、抗酸化剤、抗炎症剤、及び美白剤、並びに、化粧料 |
JP2022190111A (ja) * | 2020-11-25 | 2022-12-22 | 大正製薬株式会社 | 経口固形組成物 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080090169A (ko) * | 2007-04-04 | 2008-10-08 | (주) 아디포젠 | 쑥 또는 율피 추출물 또는 이로부터 분리된 스코파론을함유하는 체중조절용 조성물 |
KR100868261B1 (ko) | 2007-04-30 | 2008-11-11 | 한국식품연구원 | 근력 향상 활성을 갖는 조성물 |
KR100903030B1 (ko) * | 2007-08-23 | 2009-06-18 | 주식회사 안지오랩 | 멜리사엽 추출물 분획 및 이를 포함하는 조성물 |
EP2060192B9 (en) * | 2007-10-17 | 2016-05-04 | Rudolf Wild GmbH & Co. KG | Composition comprising lemon balm extracts |
JP5503125B2 (ja) * | 2008-08-08 | 2014-05-28 | 静岡県公立大学法人 | 内臓脂肪蓄積抑制剤 |
CN101361774B (zh) * | 2008-09-01 | 2012-01-25 | 北京世纪博康医药科技有限公司 | 一种含有褐藻多糖硫酸酯和人参的组合物和其应用 |
KR101108376B1 (ko) | 2009-04-08 | 2012-01-30 | 바이오스펙트럼 주식회사 | 아테미신 산을 함유하는 항비만, 항지방용 조성물 |
KR101326932B1 (ko) * | 2009-11-26 | 2013-11-11 | (주)아모레퍼시픽 | 퍼옥시좀 증식체 활성화 수용체 델타의 활성촉진 조성물 |
US20130052284A1 (en) * | 2011-08-29 | 2013-02-28 | Carolyn J. Harrington | Palm kernel oil-based intranasal composition and use |
WO2013181296A2 (en) * | 2012-05-29 | 2013-12-05 | Unigen, Inc. | Compositions and methods for managing weight |
KR101539289B1 (ko) * | 2013-08-16 | 2015-07-24 | 한국국제대학교 산학협력단 | 개똥쑥 추출물을 함유하는 지방간 또는 비만의 예방 또는 치료용 조성물 |
JP2014097987A (ja) * | 2013-12-17 | 2014-05-29 | Shizuokaken Koritsu Daigaku Hojin | 内臓脂肪蓄積抑制剤 |
EP3091975B1 (en) | 2014-01-10 | 2020-08-26 | Société des Produits Nestlé S.A. | Maternal vitamin b6 administration for the prevention of increased adiposity, overweight or obesity in the offspring |
WO2015104391A1 (en) | 2014-01-10 | 2015-07-16 | Nestec S.A. | Maternal vitamin b12 administration for the prevention of increased adiposity, overweight or obesity in the offspring especially offspring overweight and/or obese mothers |
KR20160118552A (ko) | 2015-04-02 | 2016-10-12 | 계명대학교 산학협력단 | 칡잎 추출물을 유효성분으로 함유하는 비만 예방 또는 치료용 약학조성물 |
KR101885949B1 (ko) * | 2015-12-24 | 2018-08-06 | 오좌섭 | 광대나물 추출물을 이용한 항비만용 조성물 |
KR101915071B1 (ko) | 2016-12-01 | 2018-11-20 | 주식회사 코시스바이오 | 커피 로부스타 발효 추출물을 유효성분으로 포함하는 비만 예방 및 개선용 식품 조성물 |
KR101802696B1 (ko) | 2017-02-15 | 2017-11-28 | 계명대학교 산학협력단 | 칡잎 추출물을 유효성분으로 함유하는 비만 예방 또는 치료용 약학조성물 |
CN108902939A (zh) * | 2018-06-23 | 2018-11-30 | 袁维寨 | 一种用于减肥的组合物 |
KR20200053344A (ko) | 2018-11-08 | 2020-05-18 | 충남대학교산학협력단 | 펙티넥스를 처리한 뽕나무 잎 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학 조성물 |
CN109511848A (zh) * | 2018-12-11 | 2019-03-26 | 北京康比特体育科技股份有限公司 | 一种具有减肥功能的代餐组合物 |
KR102125244B1 (ko) * | 2018-12-14 | 2020-06-23 | 주식회사 휴앤코스메틱 | 지방 분해용 조성물 |
WO2020197041A1 (ko) * | 2019-03-25 | 2020-10-01 | 임재선 | 레몬밤 추출물을 유효성분으로 포함하는 주사제 및 화장료 조성물 |
KR102036186B1 (ko) * | 2019-03-25 | 2019-10-24 | 임재선 | 레몬밤 추출물을 유효성분으로 포함하는 지방 분해용 주사제 조성물 |
KR20200135621A (ko) | 2019-05-23 | 2020-12-03 | 주식회사 하람 | 퀘르세틴-3-o-글루쿠로니드를 유효성분으로 하는 비만 예방 및 치료소재 |
KR102143084B1 (ko) * | 2019-10-08 | 2020-08-11 | 주식회사 뉴트라코어 | 비만, 당뇨, 고지혈증 및 지방간을 포함하는 대사증후군의 예방, 개선 또는 치료용 조성물 |
CN113115881A (zh) * | 2019-12-31 | 2021-07-16 | 南京宿根花卉植物园有限公司 | 一种具有减肥功能的固体饮料 |
WO2021156184A1 (en) * | 2020-02-07 | 2021-08-12 | Dsm Ip Assets B.V. | New formulation of a plant extract |
AU2021253397A1 (en) * | 2020-04-08 | 2022-11-03 | Angiolab, Inc. | Fraction extract of melissa officinalis leaves and novel pharmaceutical composition including same |
KR20210019051A (ko) | 2021-02-10 | 2021-02-19 | 충남대학교산학협력단 | 펙티넥스를 처리한 뽕나무 잎 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학 조성물 |
CN113712206A (zh) * | 2021-09-16 | 2021-11-30 | 湖南希尔天然药业有限公司 | 一种含有桑叶dnj和桑叶肽的组合物及其制备方法 |
CN113826799A (zh) * | 2021-09-26 | 2021-12-24 | 山东森健生物科技发展有限公司 | 减肥用食品 |
CN113875952A (zh) * | 2021-10-09 | 2022-01-04 | 江西邦泰绿色生物合成生态产业园发展有限公司 | 一种减肥复合制剂及其制备方法 |
KR20230098421A (ko) | 2021-12-24 | 2023-07-04 | 주식회사 앤드메이드 | 체중 감량용 조성물 및 그 제조방법 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6140763A (ja) * | 1984-08-02 | 1986-02-27 | Osaka Chem Lab | 抗肥満食品 |
JPH11187843A (ja) * | 1997-12-25 | 1999-07-13 | Lotte Co Ltd | 肥満改善用の飲食組成物およびこれを含有する飲食物 |
JPH11335285A (ja) * | 1998-05-25 | 1999-12-07 | Toyotama Koryo Kk | 整腸・便秘改善剤およびこれを含有する飲食物並びに動物用飼料 |
JP2003105371A (ja) * | 2001-09-29 | 2003-04-09 | Kobayashi Pharmaceut Co Ltd | 便意を増進する香料組成物及び付香製品 |
JP2004217532A (ja) * | 2003-01-10 | 2004-08-05 | Maruzen Pharmaceut Co Ltd | 桑葉抽出物及びその製造方法、並びに血糖値上昇抑制用組成物及び肥満防止用組成物 |
JP2005008572A (ja) * | 2003-06-19 | 2005-01-13 | Yakult Honsha Co Ltd | リパーゼ阻害剤 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2947646C2 (de) | 1978-11-28 | 1984-12-20 | Kitasato Kenkyusho, Tokio/Tokyo | Substanz mit Interferon induzierender Aktivität, Verfahren zu ihrer Herstellung und ihre Verwendung |
FR2622110A1 (fr) | 1987-10-26 | 1989-04-28 | Marty Georges | Pile prevue pour l'utilisation du pouvoir radio-actif des plantes a des fins medicales |
JPH02256621A (ja) | 1988-12-28 | 1990-10-17 | King Jozo Kk | 抗変異原剤 |
CN1033945C (zh) * | 1992-12-09 | 1997-02-05 | 陈宗尧 | 一种保健花粉糖 |
JPH06199647A (ja) | 1992-12-28 | 1994-07-19 | Noevir Co Ltd | 美白化粧料 |
JPH07196526A (ja) | 1994-01-11 | 1995-08-01 | Takano Co Ltd | コラゲナーゼ阻害剤 |
JPH08301779A (ja) | 1995-05-01 | 1996-11-19 | Sansho Seiyaku Co Ltd | アトピー性皮膚炎用外用剤 |
JPH09241142A (ja) | 1996-03-06 | 1997-09-16 | Noevir Co Ltd | 皮膚外用剤 |
FR2751878B1 (fr) | 1996-07-30 | 1998-09-04 | Oreal | Utilisation dans une composition d'un extrait d'au moins une labiee |
KR19980021670U (ko) | 1996-10-22 | 1998-07-15 | 이영서 | 전자렌지 |
KR100257448B1 (ko) | 1997-08-01 | 2000-07-01 | 박홍락 | 항암, 기관분화유도, 암세포전이 혈관형성억제, 항산화 및 숙취해소 작용을 하는 옻나무 추출물, 이의 제조방법 및 이를 포함하는 조성물 |
JP2001516712A (ja) | 1997-09-12 | 2001-10-02 | ザ、プロクター、エンド、ギャンブル、カンパニー | 皮膚又は毛髪用クレンジング及びコンディショニング製品 |
JP3796340B2 (ja) | 1997-11-18 | 2006-07-12 | 株式会社ノエビア | セリンプロテアーゼ阻害剤 |
FR2788438B1 (fr) * | 1999-01-14 | 2003-10-03 | Arkopharma Laboratoires | Composition pour le traitement de l'obesite et procede de traitement esthetique |
US20010024664A1 (en) | 1999-03-19 | 2001-09-27 | Obukowicz Mark G. | Selective COX-2 inhibition from edible plant extracts |
US6485756B1 (en) | 1999-04-06 | 2002-11-26 | Collaborative Technologies, Inc. | Stable, homogeneous natural product extracts containing polar and apolar fractions |
US6261566B1 (en) | 1999-10-22 | 2001-07-17 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic compositions containing mulberry extract and retinoids |
KR100455222B1 (ko) * | 1999-12-31 | 2004-11-06 | 주식회사 한국인삼공사 | 다이어트 인삼복합제품 및 그 제조방법 |
US6416769B1 (en) | 2000-03-03 | 2002-07-09 | Australian Importers, Ltd. | Cosmetic compositions comprising exfoliating enzymes and uses thereof |
EP1349558B1 (en) * | 2000-12-12 | 2011-06-15 | Angiolab, Inc. | Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
DE10065832A1 (de) * | 2000-12-21 | 2002-06-27 | Bettina Kater | Mittel zur Gewichtsreduktion auf der Basis Minze, Melisse und Fenchel |
KR100451962B1 (ko) | 2001-07-18 | 2004-10-08 | 주식회사 대창중기계 | 지중 물막이 연속벽 구축 공법 및 장치 |
AU2002335689B2 (en) * | 2001-08-31 | 2008-08-07 | Rutgers, The State University Of New Jersey | Methods for treating disorders using plant extracts |
KR100496622B1 (ko) * | 2002-04-29 | 2005-06-29 | (주) 김형민한약연구소 | 비만 억제를 위한 알콜 발효 식품 또는 약학적 조성물 및그의 제조방법 |
KR100828519B1 (ko) | 2002-07-12 | 2008-05-13 | 삼성전자주식회사 | 액정 패널과 이를 갖는 액정 표시 장치 |
AU2003256104A1 (en) * | 2002-08-14 | 2004-03-03 | Bionutrigen Co., Ltd | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them |
KR100569792B1 (ko) | 2003-01-14 | 2006-04-10 | 학교법인 인제학원 | 인진쑥올리고당 aip1을 함유한 항비만성 바이오헬스 소재 |
KR20030026939A (ko) * | 2003-01-27 | 2003-04-03 | 최미회 | 구아바잎을 주성분으로한 당뇨병치료용, 비만개선용,노화방지용차의 효과적인 조성물 및 이를 함유한 건강식품 |
US6908573B2 (en) | 2003-04-17 | 2005-06-21 | General Electric | Polymeric resin blends and methods of manufacture thereof |
KR100549698B1 (ko) | 2003-07-12 | 2006-02-08 | 영 욱 김 | 활성탄 섬유를 이용한 발열구조 및 이를 적용한 전열기구 |
KR100521582B1 (ko) | 2003-07-15 | 2005-10-17 | 현대자동차주식회사 | 차량 시트의 사이드 팽창장치 |
KR100624488B1 (ko) * | 2004-02-03 | 2006-09-19 | 제일약품주식회사 | 비만의 예방 및 치료용 조성물 |
KR100716066B1 (ko) | 2004-02-21 | 2007-05-08 | 변상요 | 두충엽 추출물 및 상엽 추출물을 포함하는 비만억제 식품 |
JP4929611B2 (ja) * | 2004-04-09 | 2012-05-09 | 大正製薬株式会社 | リパーゼ阻害剤 |
KR20060070254A (ko) * | 2004-12-20 | 2006-06-23 | 김정훈 | 비만조절용 건강보조식품 및 그 제조방법 |
US20060280700A1 (en) * | 2005-06-08 | 2006-12-14 | Isler Stuart L | Oral hygiene system to fight the effects of aging on the mouth, gums, and teeth |
-
2005
- 2005-10-05 KR KR1020050093577A patent/KR100645385B1/ko active IP Right Grant
-
2006
- 2006-10-09 EP EP06799129.9A patent/EP1951275B8/en active Active
- 2006-10-09 BR BRPI0617988-6A patent/BRPI0617988A2/pt not_active Application Discontinuation
- 2006-10-09 JP JP2008534469A patent/JP5284097B2/ja active Active
- 2006-10-09 CA CA2624929A patent/CA2624929C/en active Active
- 2006-10-09 CN CN200680036456.7A patent/CN101277710B/zh not_active Expired - Fee Related
- 2006-10-09 WO PCT/KR2006/004049 patent/WO2007040377A1/en active Application Filing
- 2006-10-09 AU AU2006297973A patent/AU2006297973A1/en not_active Abandoned
- 2006-10-09 ES ES06799129.9T patent/ES2581336T3/es active Active
-
2008
- 2008-03-31 US US12/059,611 patent/US9155773B2/en not_active Expired - Fee Related
-
2011
- 2011-03-22 AU AU2011201268A patent/AU2011201268B2/en not_active Ceased
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6140763A (ja) * | 1984-08-02 | 1986-02-27 | Osaka Chem Lab | 抗肥満食品 |
JPH11187843A (ja) * | 1997-12-25 | 1999-07-13 | Lotte Co Ltd | 肥満改善用の飲食組成物およびこれを含有する飲食物 |
JPH11335285A (ja) * | 1998-05-25 | 1999-12-07 | Toyotama Koryo Kk | 整腸・便秘改善剤およびこれを含有する飲食物並びに動物用飼料 |
JP2003105371A (ja) * | 2001-09-29 | 2003-04-09 | Kobayashi Pharmaceut Co Ltd | 便意を増進する香料組成物及び付香製品 |
JP2004217532A (ja) * | 2003-01-10 | 2004-08-05 | Maruzen Pharmaceut Co Ltd | 桑葉抽出物及びその製造方法、並びに血糖値上昇抑制用組成物及び肥満防止用組成物 |
JP2005008572A (ja) * | 2003-06-19 | 2005-01-13 | Yakult Honsha Co Ltd | リパーゼ阻害剤 |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF ETHNOPHARMACOLOGY, vol. 99(3), JPN6012022280, 14 July 2005 (2005-07-14), pages 391 - 398, ISSN: 0002270869 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008050301A (ja) * | 2006-08-24 | 2008-03-06 | Prima Meat Packers Ltd | 膵リパーゼ阻害剤 |
JP2016189757A (ja) * | 2015-03-31 | 2016-11-10 | 株式会社東洋新薬 | 除脂肪体重の増加剤 |
JP2020164486A (ja) * | 2019-03-29 | 2020-10-08 | 丸善製薬株式会社 | 抗老化剤、抗酸化剤、抗炎症剤、及び美白剤、並びに、化粧料 |
WO2020203933A1 (ja) * | 2019-03-29 | 2020-10-08 | 丸善製薬株式会社 | 抗老化剤、抗酸化剤、抗炎症剤、及び美白剤、並びに、化粧料 |
JP2022190111A (ja) * | 2020-11-25 | 2022-12-22 | 大正製薬株式会社 | 経口固形組成物 |
JP7338772B2 (ja) | 2020-11-25 | 2023-09-05 | 大正製薬株式会社 | 経口固形組成物 |
Also Published As
Publication number | Publication date |
---|---|
CA2624929C (en) | 2013-10-01 |
BRPI0617988A2 (pt) | 2011-08-16 |
EP1951275B1 (en) | 2016-05-18 |
ES2581336T3 (es) | 2016-09-05 |
CN101277710A (zh) | 2008-10-01 |
EP1951275A4 (en) | 2010-05-05 |
CA2624929A1 (en) | 2007-04-12 |
US20080187606A1 (en) | 2008-08-07 |
US9155773B2 (en) | 2015-10-13 |
EP1951275B8 (en) | 2016-08-10 |
JP5284097B2 (ja) | 2013-09-11 |
AU2011201268B2 (en) | 2012-01-12 |
CN101277710B (zh) | 2014-12-03 |
WO2007040377A1 (en) | 2007-04-12 |
EP1951275A1 (en) | 2008-08-06 |
KR100645385B1 (ko) | 2006-11-23 |
AU2006297973A1 (en) | 2007-04-12 |
AU2011201268A1 (en) | 2011-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5284097B2 (ja) | 抗肥満組成物 | |
JP2009511468A5 (ja) | ||
EP1763359B1 (en) | Use of pregnane glycosides in the treatment/management of obesity | |
CN1058614C (zh) | 植物制剂组合物 | |
RU2701567C1 (ru) | Средство, обладающее гепатопротекторной активностью | |
CN104857154A (zh) | 一种治疗“三高”症的中药组合物及其制备方法 | |
CN106999532A (zh) | 含有复合提取物的运动执行能力增强及体力增进用组合物 | |
KR20110105627A (ko) | 누에 체액을 함유하는 항비만 조성물 | |
KR100500373B1 (ko) | 숙취해소용 조성물 | |
US20040097429A1 (en) | Method for the reduction of the mammalian appetite | |
CN102178798A (zh) | 一种用于降低血脂、防治心脑血管疾病的制剂 | |
KR101511364B1 (ko) | 복합 생약재를 이용한 비만 및 대사증후군의 예방 또는치료용 조성물 | |
KR100595459B1 (ko) | 비만 억제용 조성물 | |
KR20020074905A (ko) | 무 추출물을 함유하는 한방 건강보조식품 조성물 | |
CN101143203A (zh) | 一种具有护肝养胃功能的复方口服液 | |
US20200276258A1 (en) | Pharmaceutical composition for controlling blood sugar | |
Jenkins et al. | Herbal Infusions and Women’s Health: A Review of Findings with a Focus on Human Studies on Specific Infusions with Studies on Extracts to Evaluate Mechanisms | |
KR100573590B1 (ko) | 비만치료ㆍ억제용 생약 조성물 | |
KR20070090835A (ko) | 지각 추출물을 함유하는 당뇨병 치료 조성물 및 이를유효성분으로 하는 건강보조식품 | |
KR20040010854A (ko) | 생약소재에 의한 변비 개선용 농축액 및 그 제조방법과용도 | |
JP4465963B2 (ja) | 高脂血症の予防または改善用組成物 | |
KR20210047897A (ko) | 대사증후군을 치료하는 중약 조성물 및 그 제제 | |
TW201402139A (zh) | 用以降血脂的中草藥萃取混合物及其醫藥組合物 | |
CN113382726A (zh) | 适用于降低超重受试者的体重指数和内脏脂肪的橄榄果提取物 | |
US20100040704A1 (en) | Composition and method for weight reduction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101001 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120416 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120501 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120509 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120710 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121009 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121010 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130222 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130430 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130529 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5284097 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |